A four-amino-acid peptide modeled on a Russian pineal gland extract and sold as an anti-aging and sleep peptide. Its reputation rests on telomerase activation in cell cultures and on decades-old Russian studies of the extract it was copied from, rather than on independent trials of the peptide itself. It is not approved, and the FDA has flagged compounded epitalon as a safety risk.
The central claim is that epitalon switches on telomerase, the enzyme that rebuilds the protective caps at the ends of chromosomes. In cultured human fetal fibroblasts it induced the telomerase catalytic subunit and lengthened telomeres, and a 2025 study found dose-dependent telomere lengthening in normal cells through telomerase and, in breast cancer cell lines, through a separate pathway called ALT. In stimulated blood lymphocytes from 11 men, incubation with the peptide changed telomere length in 7, lengthening in 5 and shortening in 2. Those are test-tube effects on cells rather than measurements in a living person.
Injected peptide (1/7)
Epitalon, a peptide of 4 amino acids, is injected and carried in the blood.
Its developers also propose that, being so small, it enters the nucleus and alters gene activity, which they link to melatonin synthesis and circadian genes in the pineal gland. A 2025 overview lists effects on melatonin, interleukin-2, thymocyte activity, and several enzymes, and concedes that the mechanisms remain uncertain and the physical and chemical characterization of the peptide is limited. In female rats kept under constant or natural northern light, the peptide extended maximum lifespan and slowed spontaneous tumors, but did nothing under a standard light cycle. The fact that it lengthens telomeres in cancer cells is a reason for caution rather than reassurance.
Epitalon is sold online for longevity, sleep, and eye health. The human studies behind those claims mostly used Epithalamin, a bovine pineal extract, in elderly Russian and Ukrainian patients, where a 6 to 8 year observation of 266 people reported fewer respiratory infections and lower mortality in treated groups. A separate report claimed a positive effect on retinal degeneration in 90% of patients, without a control group described in the abstract. Those studies come from the institute that developed the peptides and have not been reproduced elsewhere.
The synthetic tetrapeptide, Ala-Glu-Asp-Gly, was designed from the amino acid composition of that extract and later found within it. No controlled trial has defined a dose or route in humans. The FDA lists compounded epitalon among substances that may present significant safety risks, and in July 2026 its compounding advisory committee voted 7 to 5 to let pharmacies compound it for insomnia, a recommendation the FDA still has to accept or reject. Health Canada names it among unauthorized injectable peptides it has seized.
The literature is large but lopsided: cell culture, animal, and biomarker studies plus older regional human reports, nearly all from the Saint Petersburg group that developed the peptide. The strongest human claim, lower mortality over 6 to 8 years in 266 elderly people, used the pineal extract Epithalamin rather than synthetic epitalon and was not blinded. Rat studies showed lifespan effects only under abnormal lighting. The 2025 cell-line paper is the first to quantify the telomerase pathway in different cell types.
No independent, modern, controlled trial of synthetic epitalon in humans has been published. Whether telomere changes in cells mean anything for aging in a person is itself contested, and the cancer-cell findings raise a safety question no trial has addressed. Product identity is central, since the extract studied decades ago, the synthetic peptide, and the vials sold online are three different things. The July 2026 advisory vote was about compounding rather than approval and added no new trial evidence.
Reported side effects in the published human studies are few, which mainly reflects how little systematic safety data were collected. The FDA notes that compounded epitalon may pose a risk of immune reactions because of aggregation and peptide impurities and that it has no safety information for the proposed route of administration. Because the peptide activates telomerase and lengthens telomeres in cancer cell lines, an unanswered question is whether it could help an existing tumor grow. Products sold online add the usual risks of unknown dose and purity.
No regulator has approved this compound, and no company is seeking approval.
Epitalon is not approved by the FDA or any other regulator. The FDA lists compounded drugs containing epitalon among bulk substances that may present significant safety risks, citing possible immunogenicity from aggregation and impurities and a lack of safety information. In July 2026 its Pharmacy Compounding Advisory Committee voted 7 to 5, with one abstention, to recommend letting pharmacies compound it for insomnia, a recommendation the FDA still has to accept or reject. Health Canada names epitalon among unauthorized injectable peptide drugs it has seized.